Abstract:Abstract Background A major discovery in human etiology recognized that cervical cancer is a consequence of an infection caused by some mucosatropic types of human papillomavirus (HPV). Since L1 protein of HPV is able to induce the formation of neutralizing antibodies, it becomes a protein target to develop HPV vaccines. Therefore, this study aims to obtain and analyze the expression of HPV subunit recombinant protein, namely L1 HPV 52 in E. coli BL21 DE3. The raw material used was L1 HPV 52 protein, while the synthetic gene, which is measured at 1473 bp in pD451-MR plasmid, was codon-optimized (ATUM) and successfully integrated into 5643 base pairs (bps) of pETSUMO. Bioinformatic studies were also conducted to analyze B cell epitope, T cell epitope, and immunogenicity prediction for L1HPV52 protein. Results The pETSUMO-L1HPV52 construct was successfully obtained in a correct ligation size when it was cut with EcoR I. Digestion by Eco RI revealed a size of 5953 and 1160 bps for both TA cloning petSUMO vector and gene of interest, respectively. Furthermore, the right direction of construct pETSUMO-L1HPV52 was proven by PCR techniques using specific primer pairs then followed by sequencing, which shows 147 base pairs. Characterization of L1 HPV 52 by SDS-PAGE analysis confirms the presence of a protein band at a size of ~55 kDa with 6.12 mg/L of total protein concentration. Observation under by transmission electron microscope demonstrates the formation of VLP-L1 at a size between 30 and 40 nm in assembly buffer under the condition of pH 5.4. Based on bioinformatics studies, we found that there are three B cell epitopes (GFPDTSFYNPET, DYLQMASEPY, KEKFSADLDQFP) and four T cell epitopes (YLQMASEPY, PYGDSLFFF, DSLFFFLRR, MFVRHFFNR). Moreover, an immunogenicity study shows that among all the T cell epitopes, the one that has the highest affinity value is DSLFFFLRR for Indonesian HLAs. Conclusion Regarding the achievement on successful formation of L1 HPV52-VLPs, followed by some possibilities found from bioinformatics studies, this study suggests promising results for future development of L1 HPV type 52 vaccine in Indonesia.

Expression of Genetically Modified Human Papillomavirus Type 58 L1 Gene and Production of Antisera Against Resultant VLP

Human Papillomavirus L1 Protein Expressed in Escherichia Coli Self-Assembles into Virus-Like Particles That Are Highly Immunogenic.

Expression and Purification of HPV58 E1 Protein and Preparation of Polyclonal Antibodies against HPV 58 E1 Protein

Construction, Expression, Purification and Identification of Chimeric HPV16 E7-L1 Virus Like Particles

Prokaryotic Expression and Purification of Minor Capsid Protein L2 Derived from Human Papillomavirus 58 and Preparation of Monoclonal Antibody

Expression of human papillomavirus type16 late gene (L1) in prokaryotic cells and its immune effict observation

Expression and purification of HPV 18 L1 virus like particles and preparation of guinea pig antiserum against HPV 18 L1 VLP

A novel C-terminal modification method enhanced the yield of human papillomavirus L1 or chimeric L1-L2 virus-like particles in the baculovirus system

Expression, purification, and characterization of self-assembly virus-like particles of capsid protein L1 HPV 52 in Pichia pastoris GS115

Construction, expression, and in vitro assembly of virus-like particles of L1 protein of human papillomavirus type 52 in Escherichia coli BL21 DE3

N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro

Recombinant Expression of Truncated Human Papillomavirus 58 L1 Protein with Molecular Chaperones in E.coli

Expression, Purification, Bio-Physical Properties and Immunogenicity in BALB/c Mice

Construction of a Chimeric Gene of Human Papillomavirus Type 16 L1-E7 and Immunogenicity of Expressed Fusion Protein

Advance in Human Papillomavirus Major Capsid Protein L1-based Vaccines

Identification of the mimotopes within the major capsid protein L1 of human papillomavirus types 18 and 45, using neutralizing monoclonal antibodies

Production of codon-optimized Human papillomavirus type 52 L1 virus-like particles in Pichia pastoris BG10 expression system

Immunogenicity of Plant-Produced Human Papillomavirus (HPV) Virus-Like Particles (VLPs)

[Cloning and Expressing of Human Papillomavirus 16 E7C Subgene].

[Study on the Frequency of Human Papillomavirus Type 6 and Type 11 Infection and L1 Gene Expression of the Virus in Biopsy Samples of Pointed Condyloma Patients].

Characterization of a triple-type chimeric vaccine against human papillomavirus types 18, 45, and 59